Celltrion Recalls One Lot of Steqeyma

On Aug. 13, 2025, Celltrion USA initiated a recall of one lot of Steqeyma^® (ustekinumab-stba) 90 mg/mL injection due to incorrect assembly and release into the market. Steqeyma is a human interleukin-12 and -23 antagonist indicated for the treatment of adult patients who have moderate to severe plaque psoriasis (PsO) and are candidates for phototherapy or systemic therapy, active psoriatic arthritis (PsA), moderately to severely active Crohn’s disease (CD) and moderately to severely active ulcerative colitis. It is also indicated for pediatric patients ages six years and older who have moderate to severe plaque psoriasis and are candidates for phototherapy or systemic therapy, as well as those who have active PsA. For more information on the recall, see here.